The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Yuqin Song | ASH 2018 | Tislelizumab (BGB-A317) in relapsed/refractory classical Hodgkin lymphoma

Dec 21, 2018

60 thASH Annual Meeting & Exposition, December 1-4 2018, San Diego, CA
Yuqin Song
Peking University Cancer Hospital, Beijing, CN

Interview Topic: Tislelizumab (BGB-A317) in relapsed/refractory classical Hodgkin lymphoma

Tislelizumab (BGB-A317) in relapsed/refractory classical Hodgkin lymphoma